Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22552847 | 0.86 | ALDH1A1 (0.44) | FAAHMAPTABCC4ALDH1A1TSHR | |
| SCHEMBL22552845 | 0.86 | ALDH1A1 (0.44) | FAAHMAPTABCC4ALDH1A1TSHR | |
| SCHEMBL10368812 | 0.84 | MAPT (0.47) | FAAHMAPTABCC4ALDH1A1TSHR | |
| SCHEMBL22367767 | 0.83 | MAPT (0.39) | FAAHMAPTABCC4ALDH1A1TSHR | |
| SCHEMBL20819989 | 0.83 | MAPT (0.34) | FAAHMAPTABCC4ALDH1A1USP2 | |
| SCHEMBL22552623 | 0.83 | MAPT (0.34) | FAAHMAPTABCC4ALDH1A1USP2 | |
| SCHEMBL5495937 | 0.81 | MTNR1A (0.33) | MAPTSMN1; SMN2DDAH1 | |
| SCHEMBL976765 | 0.80 | GRIK1 (0.39) | TP53MAPTABCC4TSHR | |
| SCHEMBL15698565 | 0.80 | TSHR (0.39) | FAAHMAPTABCC4ALDH1A1TSHR | |
| SCHEMBL27696125 | 0.80 | TSHR (0.39) | FAAHMAPTABCC4ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2192109-B1 | BICYCLIC -AMINO ACID DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-7947738-B2 | Bicyclic γ-amino acid derivative | DAIICHI SANKYO COMPANY, LTD. (JP) | 2011-05-24 | — | — | US | disclosed |
| US-20100249229-A1 | BICYCLIC gamma-AMINO ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LTD. (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2192109-A1 | BICYCLIC -AMINO ACID DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2010-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249229-A1 | BICYCLIC gamma-AMINO ACID DERIVATIVE | GLRA2, GLRB, BCAT1 | FAAH 1192/4885TP53 3766/4885MAPT 3962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.